Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type. Issue 5 (5th April 2019)

• Record Type: Journal Article
• Authors: Al Dhafiri, Mahdi; Sicre de Fontbrune, Flore; Marinho, Eduardo; Deschamps, Lydia; Di‐Lucca, Julie; Crickx, Beatrice; Descamps, Vincent
• Is Part Of: Clinical case reports. Volume 7:Issue 5(2019)
• Page Start: 964
• Page End: 967
• Publication Date: 2019-04-05
• Subjects: chemotherapy -- leg type -- lenalidomide -- primary cutaneous diffuse large B‐cell lymphoma; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2137
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT. Abstract : The primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) has a poor prognosis. R‐CHOP with or without radiotherapy is the available recommendations for first‐line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second‐line treatment of relapsed PCDLBCL‐LT.